4-AcO-DiPT

Discovery

4-OH-DiPT, the pharmacologically active form of 4-AcO-DiPT, was first synthesized in 1977 by David B. Repke, William J. Ferguson, and David K. Bates as part of a series of psilocin analogs.^[5] The original publication reported only the chemical synthesis — no pharmacological or human data were included. Twenty years later, Alexander Shulgin documented 4-OH-DiPT's human effects in TiHKAL (1997), reporting rapid onset, brief duration, and a phenomenology marked by stimulation, elation, and introspection.^[2]

Grey-market emergence

4-AcO-DiPT — the acetate ester prodrug — appeared on grey markets as a novel designer drug around 2005.^[6] Chapman (2017) confirmed structural identity of grey-market tryptamine samples, including 4-AcO-DiPT, via NMR spectroscopy; none were found to be misrepresented.^[10] In January 2022 the U.S. DEA proposed scheduling 4-OH-DiPT under Schedule I, but withdrew the rule in July 2022 pending further evaluation.^[11]

Modern clinical development

The 4-OH-DiPT pharmacological class entered clinical development through Reunion Neuroscience, which created RE104 — a glutarate ester prodrug distinct from the acetate ester in 4-AcO-DiPT. RE104 produced antidepressant-like effects in animal models^[8] and has completed Phase 2 trials in postpartum depression,^[7] with additional trials in adjustment disorder^[12] and generalized anxiety disorder underway.

Structural class

4-AcO-DiPT belongs to the 4-substituted tryptamine family — specifically the acetate ester prodrugs of 4-hydroxyindole psychedelics. The indole ring system bears an aminoethyl chain at position 3 and an acetoxy group at position 4. The N,N-diisopropyl substitution differentiates it from 4-AcO-DMT (N,N-dimethyl) and 4-AcO-MET (N-methyl-N-ethyl).

As an acetate ester, 4-AcO-DiPT is hydrolyzed in vivo to yield 4-OH-DiPT — the pharmacologically active metabolite.^[1] This prodrug relationship parallels that of psilocybin to psilocin and 4-AcO-DMT to psilocin.

Molecular properties

The two isopropyl groups on the amine nitrogen create significant steric bulk compared to smaller N-alkyl tryptamines, reducing receptor binding potency relative to dimethyl and diethyl analogs.^[13][14]

Stereochemistry

4-AcO-DiPT contains no chirality centers. The sp³ nitrogen bearing two isopropyl groups undergoes rapid pyramidal inversion; the compound exists as a single constitutional isomer without enantiomeric or diastereomeric forms.

Physical properties

No published characterization of the melting point, solubility, or stability parameters exists in peer-reviewed literature. Chapman (2017) confirmed structural identity of grey-market samples via NMR but did not report physical constants.^[10] The acetate ester is expected to hydrolyze under acidic or basic aqueous conditions and in the presence of esterases, consistent with its prodrug function.

Mechanism of action

4-AcO-DiPT is a prodrug: hepatic esterases cleave the acetate group to release 4-OH-DiPT, the pharmacologically active metabolite.^[1] All psychoactive effects stem from this conversion.

4-OH-DiPT's primary target is the 5-HT₂A receptor, where it acts as a near-full agonist — the same receptor responsible for the effects of psilocybin and LSD. It also activates serotonin₂B and 5-HT₂C receptors with comparable potency at both mouse and human receptor forms.^[3]

Unusually for a classical psychedelic, 4-OH-DiPT also interacts with the SERT (SERT) and NET (NET) — a transporter profile more similar to MDMA than to LSD or mescaline.^[4] The related compound DiPT acts as a SERT substrate rather than a blocker, meaning it may accumulate within serotonergic neurons.^[15]

Pharmacokinetics

No human pharmacokinetic studies exist for 4-AcO-DiPT. Oral bioavailability has not been measured, though acetate ester prodrugs of tryptamines are generally assumed to improve oral absorption relative to free hydroxy forms.

In rats, 4-OH-DiPT showed a plasma half-life of approximately 40 minutes after subcutaneous administration of a related prodrug (RE104).^[8] Shulgin reported 4-OH-DiPT duration as 2–3 hours oral;^[2] the 3–4 hour total duration observed with 4-AcO-DiPT is consistent with additional time required for prodrug conversion.^[8][16]

DiPT-class compounds inhibit CYP2D6 in laboratory studies,^[17] which is potentially relevant when combined with medications metabolized by this enzyme — including many antidepressants and opioids. Clinical significance has not been confirmed in humans.

Where it acts

The most detailed neural data for 4-AcO-DiPT come from studies of its active metabolite in mice. 4-OH-DiPT activates inhibitory interneurons in the basolateral amygdala (BLA) via 5-HT₂A receptors, suppressing the output of fear-signaling neurons.^[3] This interneuron-mediated inhibition reduced freezing in fear extinction paradigms, with greater potency in female than male mice — consistent with broader evidence that serotonergic psychedelics dampen amygdala reactivity.

The additional SERT and NET interactions^[4][15] may contribute entactogenic-type neural effects — enhanced emotional openness and reduced threat sensitivity — layered on top of classical psychedelic perceptual changes.

Why it matters

The amygdala data fit the REBUS (Relaxed Beliefs Under Psychedelics) model: by inhibiting fear-circuit output, 4-OH-DiPT may loosen the brain's weighting of threat-related expectations, facilitating the extinction of maladaptive fear responses. The antidepressant-like effects of RE104 persisting one week after administration in rats^[8] are consistent with lasting structural brain changes (neuroplasticity) rather than acute drug action alone.

Toxicity

No lethal dose data have been published for 4-AcO-DiPT or 4-OH-DiPT in any species. No case reports of adverse events, overdose, or fatalities specifically involving 4-AcO-DiPT have been identified.^[18] The toxic dose is unknown.

Psychological risks

No controlled studies have assessed psychological risks specific to 4-AcO-DiPT. Risks are inferred from the serotonergic psychedelic class:

• Acute psychological distress — anxiety, panic, paranoia, and challenging experiences occur with all 5-HT₂A agonist psychedelics and scale with dose, predisposition, and setting.
• Hallucinogen persisting perception disorder (HPPD) — persistent visual disturbances following psychedelic use have been documented for the broader class.^[20][21] No substance-specific data exist for 4-AcO-DiPT.
• Psychosis precipitation — individuals with personal or family history of psychotic disorders face elevated risk from 5-HT₂A agonist psychedelics.

Tolerance and dependence

Tolerance develops through downregulation of the 5-HT₂A receptor.^[22] Notably, DiPT — the backbone compound of 4-AcO-DiPT — does not develop tolerance to psychedelic-like responses with daily dosing in mice, unlike phenethylamine hallucinogens.^[23] This suggests tolerance development in the DiPT series may be less robust than commonly assumed.

Cross-tolerance with other serotonergic psychedelics (psilocybin, LSD, mescaline) is expected based on shared 5-HT₂A receptor downregulation.^[22][23] The tryptamine psychedelic class is considered to carry low abuse liability.^[9]

Drug interactions

Tramadol elevates serotonin syndrome risk through its own serotonergic activity.^[24] No published study has directly tested this combination with 4-AcO-DiPT; the severity rating is class-based. safety citation needed

SSRIs and SNRIs increase serotonergic load when combined with 5-HT₂A agonist tryptamines. Chronic SSRI use typically blunts psychedelic effects, but the SERT substrate properties of the DiPT class add complexity: SSRIs block the transporter through which DiPT-class compounds enter neurons.^[15]

Contraindications

Absolute contraindications (inferred from class pharmacology):

• Psychotic disorders or family history of psychosis — 5-HT₂A agonist psychedelics may trigger or worsen psychotic episodes.
• Concurrent MAOI use — critical serotonin syndrome risk given SERT substrate properties of the DiPT class.^[15]
• Concurrent lithium use — class-level seizure risk. safety citation needed

Relative contraindications:

• Bipolar disorder — risk of manic episode.
• Heart conditions — 4-OH-DiPT's 5-HT₂B agonism^[3] represents an unstudied risk for individuals with pre-existing valve disease.
• Pregnancy and breastfeeding — no reproductive safety data exist.

4-AcO-DiPT occupies an ambiguous legal position in most jurisdictions. It is not specifically scheduled under many national drug control frameworks, but its status as an ester of 4-OH-DiPT — or as a structural analog of controlled tryptamines — may bring it within scope of analog or blanket ban legislation. Legal status varies significantly by jurisdiction and is subject to change.

Analog and prodrug considerations

In jurisdictions with analog legislation — notably the U.S. Federal Analogue Act (21 U.S.C. § 813) — 4-AcO-DiPT's structural similarity to scheduled tryptamines and its prodrug relationship to 4-OH-DiPT may render it legally equivalent to a Schedule I substance when intended for human consumption. The withdrawn 2022 DEA proposal to schedule 4-OH-DiPT directly, and its subsequent withdrawal pending further evaluation, leaves both compounds in regulatory limbo as of April 2026.^[11]